MedTrace Logo

A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices

NCT00292409 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2013-11-08

No results posted yet for this study

Summary

The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.

Conditions

  • Schizophrenia and Schizoaffective Disorder

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-11-30
Completion
2007-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00292409 on ClinicalTrials.gov